METASTATIC GASTRIC ADENOCARCINOMA
Clinical trials for METASTATIC GASTRIC ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC GASTRIC ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC GASTRIC ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise in stomach cancer trial
Disease control Recruiting nowThis study tests whether adding the drug ivonescimab to standard chemotherapy can shrink tumors better than chemo alone in people with advanced stomach or gastroesophageal cancer. About 88 participants will receive treatment every two weeks. The main goal is to see how many patie…
Matched conditions: METASTATIC GASTRIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: UNICANCER • Aim: Disease control
Last updated May 17, 2026 00:51 UTC
-
Stomach cancer patients may soon get treatment as a simple shot
Disease control Recruiting nowThis study tests if a shot under the skin works as well as an IV drip for a cancer drug (tislelizumab) combined with chemotherapy in adults with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. About 351 participants will recei…
Matched conditions: METASTATIC GASTRIC ADENOCARCINOMA
Phase: PHASE3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated May 17, 2026 00:49 UTC
-
New combo shows promise for tough stomach cancers
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy (paclitaxel and ramucirumab) helps people with advanced stomach or esophageal cancer live longer without their disease getting worse. About 224 adults whose cancer has a specific marker (PD-…
Matched conditions: METASTATIC GASTRIC ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New immune cocktail targets tough stomach cancers
Disease control Recruiting nowThis study tests a mix of immune cells (agenT-797) and three immunotherapy drugs (botensilimab, balstilimab, ramucirumab) plus chemotherapy (paclitaxel) for people with advanced stomach, esophageal, or gastro-esophageal junction cancer that has worsened after one prior treatment.…
Matched conditions: METASTATIC GASTRIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Tailor-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors. The goal is to see if this combination is safe and helps the immune system fight cancer more effectively. A…
Matched conditions: METASTATIC GASTRIC ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
Mist chemo targets stomach cancer spread in new trial
Disease control Recruiting nowThis early-phase trial tests a new method of delivering chemotherapy directly into the abdomen as a fine mist under pressure (PIPAC) for stomach cancer that has spread to the lining of the belly. The study involves 30 people whose cancer progressed after initial treatment. The go…
Matched conditions: METASTATIC GASTRIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New cocktail of cancer drugs shows promise for stomach cancer patients
Disease control Recruiting nowThis study is for people with advanced stomach cancer that has spread and who have already tried one type of treatment. It tests a combination of three drugs (ramucirumab, nal-IRI, and trifluridine/tipiracil) to see if they can shrink tumors and control the disease. The goal is t…
Matched conditions: METASTATIC GASTRIC ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Health Research Institutes, Taiwan • Aim: Disease control
Last updated May 11, 2026 20:53 UTC
-
New pill combo shows promise against hard-to-treat HER2 cancers
Disease control Recruiting nowThis study tests an experimental pill called zongertinib, which blocks HER2—a protein that makes cancer grow. It is for adults with advanced HER2+ breast, stomach, or colorectal cancer that has spread and hasn't responded to prior treatments. The study has two parts: first, findi…
Matched conditions: METASTATIC GASTRIC ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 06, 2026 16:02 UTC
-
New drug combo shows promise for tough stomach cancers
Disease control Recruiting nowThis early-phase study tests two drugs, pembrolizumab and lenvatinib, in about 15 people with advanced stomach or gastroesophageal cancer that has spread or can't be surgically removed. Pembrolizumab helps the immune system attack cancer cells, while lenvatinib blocks enzymes tha…
Matched conditions: METASTATIC GASTRIC ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 04, 2026 16:23 UTC
-
New chemo cocktail aims to extend life in hard-to-treat stomach cancers
Disease control Recruiting nowThis study compares two chemotherapy combinations for people with advanced stomach, esophageal, or gastroesophageal junction cancer that cannot be removed by surgery. About 382 participants will receive either the standard FOLFOX chemo (with or without the immunotherapy nivolumab…
Matched conditions: METASTATIC GASTRIC ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 04, 2026 16:18 UTC